Soc. Generale Call 34 LEN 20.12.2.../ DE000SW987P9 /
03/06/2024 09:53:14 | Var.0.000 | Denaro17:30:09 | Lettera17:30:09 | Sottostante | Prezzo di esercizio | Expiration date | Tipo di opzione |
---|---|---|---|---|---|---|---|
0.530EUR | 0.00% | 0.500 Quantità in denaro: 6,000 |
0.530 Quantità in lettera: 6,000 |
LENZING AG | 34.00 EUR | 20/12/2024 | Call |
GlobeNewswire
17:53
Sustainable Green Team, Ltd. (SGTM) Signs Purchase Agreement to Acquire Patents and Intellectual Pro...
GlobeNewswire
17:35
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire
17:33
Natiivo Hospitality Expands with New South Florida Projects, Hires Yoav Gery as President
GlobeNewswire
17:30
Titan.ium Platform Announces Collaboration with Nokia Improving Security for Global Telecommunicatio...
GlobeNewswire
17:20
New CryptoStaking Strategies Introduced by CryptoHeap to Maximize Investor Returns
GlobeNewswire
17:15
DEADLINE ALERT for HRT and CKPT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions...
GlobeNewswire
17:13
Los Angeles Student Wins NFTE West (Southern California) Youth Entrepreneurship Challenge
GlobeNewswire
17:12
Kirby McInerney LLP Reminds Harbor Diversified, Inc. (HRBR) Investors of Class Action Filing and Enc...
GlobeNewswire
17:11
Kirby McInerney LLP Reminds Global Cord Blood Corporation (CORBF) Investors of Upcoming Deadline in ...
GlobeNewswire
17:11
Infuse Summer Fun In Your Coffee With Bones Coffee Company’s New, Limited-Edition Summer Flavors
GlobeNewswire
17:02
Cambria Investment Management and Chesapeake Capital Corporation Announces the Launch of the Cambria...
GlobeNewswire
17:00
MidWestOne Financial Group Welcomes Three Key Executive Leaders to the Organization
GlobeNewswire
17:00
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopa...